Valeant Sheds 3 Skin-care Brands, Dendreon for $2.1B

Source: Valeant

Jan 11, 2017

Valeant Pharmaceuticals International is selling its Dendreon cancer treatment business to Sanpower as well as three skin-care brands to L'Oréal for $2.1 billion in a move to reduce its $30 billion debt. This comes after the increased pressure of its failed Salix deal with Takeda.

L'Oréal will gain the three skin-care brands, CeraVe, AcneFree and AMBI for $1.3 billion. According to a Valeant release, the three brands see an annual combined revenue of $168 million.

Dendreon is reportedly switching hands to China’s Sanpower Group for $819.9 million in cash. Dendreon makes prostate cancer treatment Provenge.

Valent is attempting to regain investor confidence after 2016 saw its stock plummet after disclosuring that it worked secretly with a specialty pharmacy to boost medicine sales.

Read the Wall Street Journal report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments